Literature DB >> 31436228

Diagnostic ability of percutaneous core biopsy immediately after microwave ablation for lung ground-glass opacity.

Jiao Wang1, Yang Ni2, Xia Yang1, Guanghui Huang1, Zhigang Wei1, Wenhong Li1, Xiaoying Han1, Min Meng1, Xin Ye2, Jiayun Lei3.   

Abstract

OBJECTIVES: The objective of this study is to determine the diagnostic ability of percutaneous core biopsy immediately after microwave ablation (MWA) for lung ground-glass opacity (GGO).
MATERIALS AND METHODS: Seventy-four patients with 74 lung GGOs were enrolled and treated with MWA. A percutaneous core needle biopsy was performed pre- and immediately post-MWA. All biopsy specimens were histologically examined by hematoxylin and eosin staining and immunostaining. Histologically, atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (AC) were identified as positive, while chronic inflammation or normal lung tissue was identified as negative.
RESULTS: The outcomes of pre-MWA histological diagnosis were AAH (n = 4), AIS (n = 16), MIA (n = 14), AC (n = 29), chronic inflammation (n = 2), and lung tissue (n = 9) with an 85.1% (63/74) positive diagnosis rate. The outcomes of the immediately post-MWA histological diagnosis were AAH (n = 5), AIS (n = 10), MIA (n = 11), AC (n = 29), chronic inflammation (n = 1), and lung tissue (n = 18) with a 74.3% (55/74) positive diagnosis rate. There was no significant difference in the positive diagnosis rate between the pre- and immediately post-MWA groups (P = 0.10). The outcomes of the combined diagnosis of pre- and immediately post-MWA were AAH (n = 4), AIS (n = 16), MIA (n = 16), AC (n = 31), chronic inflammation (n = 2), and lung tissue (n = 5) with a positive diagnosis rate of 90.5% (67/74), which was higher than that by pre-MWA biopsy (P < 0.05). The main complications were pneumothorax (n = 45, 60.8%), hemoptysis (n = 24, 32.4%), pleural effusion (n = 39, 52.7%), and pulmonary infection (n = 10, 13.5%).
CONCLUSIONS: Immediately post-MWA core biopsy has promising efficacy for histological diagnosis of lung GGOs.

Entities:  

Keywords:  Biopsy; ground-glass opacity; lung; microwave ablation

Mesh:

Year:  2019        PMID: 31436228     DOI: 10.4103/jcrt.JCRT_399_19

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

Review 1.  Advances in study of the sequence of lung tumor biopsy and thermal ablation.

Authors:  Fanlei Kong; Chengen Wang; Yunfang Li; Xiaoguang Li
Journal:  Thorac Cancer       Date:  2020-12-28       Impact factor: 3.500

2.  Comparison of Multi-Gene Testing Data Between Fresh and Formalin-Fixed Specimens From Core Needle Biopsy in Patients With NSCLC.

Authors:  Zhi-Gang Yao; Zhi-Gang Wei; Xian-Kui Cheng; Guang-Hui Huang; Yuan-Yuan Zong; Min Meng; Jia-Mei Li; Xiao-Ying Han; Jia-Wen Xu; Jiao Wang; Hai-Yan Jing; Wen-Hong Li; Zhi-Xin Cao; Yang Ni; Xi-Chao Sun; Xia Yang; Xin Ye
Journal:  Pathol Oncol Res       Date:  2021-12-13       Impact factor: 3.201

3.  Synchronous microwave ablation followed by core-needle biopsy via a coaxial cannula for highly suspected malignant lung ground-glass opacities: A single-center, single-arm retrospective study.

Authors:  FanLei Kong; ZhiXin Bie; YuanMing Li; Bin Li; RunQi Guo; ChengEn Wang; JinZhao Peng; Sheng Xu; XiaoGuang Li
Journal:  Thorac Cancer       Date:  2021-10-20       Impact factor: 3.500

4.  Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure.

Authors:  Nan Wang; Jingwen Xu; Gang Wang; Guoliang Xue; Zhichao Li; Pikun Cao; Yanting Hu; Hongchao Cai; Zhigang Wei; Xin Ye
Journal:  Thorac Cancer       Date:  2022-08-01       Impact factor: 3.223

5.  Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.

Authors:  Yang Ni; Jinchao Peng; Xia Yang; Zhigang Wei; Bo Zhai; Jiachang Chi; Xiaoguang Li; Xin Ye
Journal:  Br J Cancer       Date:  2021-06-15       Impact factor: 9.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.